Novo Nordisk A/S is working on a broad Phase III development program for a once-weekly basal insulin that could improve treatment compliance in patients with diabetes.
For many patients, the number of daily injections required is a deterrent to insulin use, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others needing to do both